The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
Abstract Background The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4613 |
| _version_ | 1818243745184743424 |
|---|---|
| author | Ren‐Shu Zhang Jie Liu Yao‐Tiao Deng Xin Wu Yu Jiang |
| author_facet | Ren‐Shu Zhang Jie Liu Yao‐Tiao Deng Xin Wu Yu Jiang |
| author_sort | Ren‐Shu Zhang |
| collection | DOAJ |
| description | Abstract Background The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and treatment patterns of anlotinib in patients with advanced STS. Methods We retrospectively analyzed the data of patients with unresectable locally advanced or metastatic STS who received at least one dose of anlotinib from June 2018 to March 2021. The survival data were analyzed using the Kaplan–Meier method and compared using the log‐rank test. The Cox proportional hazards model was performed for multivariate analysis. Results A total of 209 patients were included. The median age was 48 (range 11–85) years. The median follow‐up, progression‐free survival, and overall survival were 18.7 months, 6.1 months [95% confidence interval (CI): 4.9–7.2], and 16.4 months (95% CI: 13.6–19.1), respectively. The objective response rate was 13.4%. Nutritional status, Eastern Cooperative Oncology Group (ECOG) performance status, and anlotinib treatment patterns (combination therapy or switch maintenance therapy vs. monotherapy) were significantly associated with progression‐free survival. Besides, pathological grade, nutritional status, ECOG performance status, and anlotinib treatment patterns were predictive of overall survival. Due to anlotinib‐related toxicity, 31 (14.8%) patients, and 25 (12.0%) patients experienced dose reduction and treatment discontinuation, respectively. Conclusion These findings confirmed the efficacy of anlotinib in patients with advanced STS in a real‐world setting. The patterns of anlotinib treatment deserve further exploration. |
| first_indexed | 2024-12-12T14:06:00Z |
| format | Article |
| id | doaj.art-88ae1ed17d454314b16de9c19cfb9d9a |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-12T14:06:00Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-88ae1ed17d454314b16de9c19cfb9d9a2022-12-22T00:22:13ZengWileyCancer Medicine2045-76342022-06-0111112271228310.1002/cam4.4613The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial eraRen‐Shu Zhang0Jie Liu1Yao‐Tiao Deng2Xin Wu3Yu Jiang4Department of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu ChinaAbstract Background The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and treatment patterns of anlotinib in patients with advanced STS. Methods We retrospectively analyzed the data of patients with unresectable locally advanced or metastatic STS who received at least one dose of anlotinib from June 2018 to March 2021. The survival data were analyzed using the Kaplan–Meier method and compared using the log‐rank test. The Cox proportional hazards model was performed for multivariate analysis. Results A total of 209 patients were included. The median age was 48 (range 11–85) years. The median follow‐up, progression‐free survival, and overall survival were 18.7 months, 6.1 months [95% confidence interval (CI): 4.9–7.2], and 16.4 months (95% CI: 13.6–19.1), respectively. The objective response rate was 13.4%. Nutritional status, Eastern Cooperative Oncology Group (ECOG) performance status, and anlotinib treatment patterns (combination therapy or switch maintenance therapy vs. monotherapy) were significantly associated with progression‐free survival. Besides, pathological grade, nutritional status, ECOG performance status, and anlotinib treatment patterns were predictive of overall survival. Due to anlotinib‐related toxicity, 31 (14.8%) patients, and 25 (12.0%) patients experienced dose reduction and treatment discontinuation, respectively. Conclusion These findings confirmed the efficacy of anlotinib in patients with advanced STS in a real‐world setting. The patterns of anlotinib treatment deserve further exploration.https://doi.org/10.1002/cam4.4613clinical managementnutritionprognosissoft tissue sarcomatarget therapytyrosine kinase inhibitors |
| spellingShingle | Ren‐Shu Zhang Jie Liu Yao‐Tiao Deng Xin Wu Yu Jiang The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era Cancer Medicine clinical management nutrition prognosis soft tissue sarcoma target therapy tyrosine kinase inhibitors |
| title | The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era |
| title_full | The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era |
| title_fullStr | The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era |
| title_full_unstemmed | The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era |
| title_short | The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era |
| title_sort | real world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post alter0203 trial era |
| topic | clinical management nutrition prognosis soft tissue sarcoma target therapy tyrosine kinase inhibitors |
| url | https://doi.org/10.1002/cam4.4613 |
| work_keys_str_mv | AT renshuzhang therealworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT jieliu therealworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT yaotiaodeng therealworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT xinwu therealworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT yujiang therealworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT renshuzhang realworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT jieliu realworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT yaotiaodeng realworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT xinwu realworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera AT yujiang realworldclinicaloutcomesandtreatmentpatternsofpatientswithunresectablelocallyadvancedormetastaticsofttissuesarcomatreatedwithanlotinibinthepostalter0203trialera |